<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392951</url>
  </required_header>
  <id_info>
    <org_study_id>2006-7-4873</org_study_id>
    <nct_id>NCT00392951</nct_id>
  </id_info>
  <brief_title>Sirolimus for Autoimmune Disease of Blood Cells</brief_title>
  <official_title>Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for patients with autoimmune destruction of blood cells is poor. The part of the
      body that fights infections is called the immune system and white blood cells (WBCs) are part
      of the immune system. Normally, a person's body creates WBCs to fight infections and
      eliminates WBCs which have stopped helping the body function. Patients with autoimmune
      destruction of blood cells have difficulty eliminating old WBCs. The abnormal WBCs build up
      and can damage other healthy cells, which can lead to anemia, fatigue, jaundice, internal
      bleeding, infection, and cancer. Few effective medications exist for treatment for patients
      with autoimmune cytopenias and those commonly used are fraught with side effects.
      Nevertheless, as scientific understanding of autoimmune diseases has improved, more directed
      and less toxic therapies are becoming available. A number of groups have been studying the
      efficacy of a medication called sirolimus in patients with autoimmune diseases. This medicine
      has been FDA-approved for over 20 years. Sirolimus is a medicine used in children with other
      diseases. Sirolimus works, in part, by eliminating old and abnormal WBCs. Our group and
      others have shown that sirolimus is effective in mice with autoimmunity and in children with
      a rare condition called Autoimmune Lymphoproliferative Syndrome (ALPS). We believe sirolimus
      will help children with autoimmune cytopenias. We believe it will improve their symptoms and
      make them less sick. We propose to study sirolimus in children with chronic and/or refractory
      autoimmune cytopenias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with autoimmune destruction of hematopoietic cells frequently have severe and
      debilitating disease requiring aggressive and frequent medical management. These patients are
      often treated with non-specific immunosuppressive medications with limited efficacy and
      untoward side-effect profiles. We have been investigating the use of an immunosuppressive and
      anti-cancer agent, sirolimus in patients with an autoimmune cytopenias syndrome: Autoimmune
      Lymphoproliferative Syndrome (ALPS). ALPS is a primary immune deficiency caused by mutations
      in the Fas apoptotic pathway, leading to abnormal lymphocyte survival. Clinical
      manifestations in patients with ALPS typically include autoimmune cytopenias,
      lymphadenopathy, hepatosplenomegaly, and a propensity to develop secondary malignancies.
      Thus, far we have found excellent results albeit the total number of patients treated is
      small.

      Sirolimus is a signal transduction inhibitor with a tolerable side effect profile. Sirolimus
      has two properties making it an attractive agent to treat patients with autoimmune cytopenias
      syndromes, including ALPS. First, sirolimus induces apoptosis in normal and abnormal white
      blood cells, the cell type dysregulated in patients with autoimmune disease. In addition,
      sirolimus increases a T cell subset called Regulatory T cells (Tregs). Tregs are a cell
      population designed to suppress the immune system and control autoimmunity. These combined
      properties make sirolimus unique as compared with other immunosuppressive agents. Ample
      preclinical and clinical data exists demonstrating sirolimus in effective in patients with
      autoimmunity. Accordingly, we hypothesize sirolimus is a safe and efficacious medication for
      patients with autoimmune destruction of blood cells..

      We plan to confirm our hypotheses by performing a pilot series in children with autoimmune
      cytopenias who are either refractory to standard therapy or have significant toxicity from
      standard treatments. Our primary aim is to define the toxicities of administration of oral
      sirolimus in children with autoimmune cytopenias. Our secondary aims are to evaluate the
      efficacy of sirolimus in children with autoimmune cytopenias, to determine the trough levels
      of sirolimus when used in these patients, and to evaluate the effects of sirolimus on
      intracellular targets of mammalian target of rapamycin (mTOR). We intend to enroll 50
      children with autoimmune cytopenias and treat for a 6 month period, however, if we find
      sirolimus is effective, we anticipate these children will continue to take sirolimus for a
      longer period of time. We anticipate the results of this work will establish sirolimus is an
      effective and well tolerated medication and will lead directly to a larger national phase II
      clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus</measure>
    <time_frame>6 months</time_frame>
    <description>Grade 3 toxicities are those that are considered severe or medically equivalent requiring hospitalization or prolonged hospitalization (according to CTCAE criteria 3.0).
Grade 4 toxicities are those that are life-threatening (urgent intervention indicated) (according to CTCAE criteria 3.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Autoimmune Disease Response to Oral Sirolimus</measure>
    <time_frame>6 months</time_frame>
    <description>Complete response (CR) is complete resolution in all autoimmune cytopenias (neutropenia, anemia thrombocytopenia) maintained for more than two months, combined with an ability to wean off corticosteroids and/or other immunosuppressive medication. Partial response (PR) is improvement in any cytopenias by at least one grade, lasting more than two months, without worsening any other cytopenias or stable disease with the ability to wean corticosteroids and/or immunosuppressive medications by at least 50%. No response (NR) is no change in cytopenias with treatment, and the inability to wean corticosteroids or other immunosuppressive medications. Progressive disease (PD) refers to obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels Produced by Administration of Oral Sirolimus</measure>
    <time_frame>Within first 5 days of starting sirolimus</time_frame>
    <description>Pharmacokinetic levels produced by administration of oral sirolimus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Sirolimus on Intracellular Targets</measure>
    <time_frame>6 months</time_frame>
    <description>Needs more specific information</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Lymphoproliferation Response to Oral Sirolimus</measure>
    <time_frame>6 months</time_frame>
    <description>Complete response (CR) is complete resolution of any lymphadenopathy and splenomegaly for at least two months. Partial response (PR) is a reduction in size of at least 50% of lymphadenopathy or splenomegaly for at least two months. No response (NR) is no change or &lt; 50% reduction in lymphadenopathy or splenomegaly. Progressive Disease (PD) is obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug. Not Applicable (N/A) is there is no evidence of disease (No pathologic lymphadenopathy or splenomegaly at time of enrollment).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Autoimmune Pancytopenia</condition>
  <condition>Autoimmune Lymphoproliferative Syndrome (ALPS)</condition>
  <condition>Evans Syndrome</condition>
  <condition>Idiopathic Thrombocytopenic Purpura</condition>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <condition>Autoimmune Neutropenia</condition>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sirolimus treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
    <arm_group_label>Sirolimus treatment</arm_group_label>
    <other_name>rapamycin</other_name>
    <other_name>rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 12 months and &lt; 30 years at the time of study entry

          -  Diagnosis of autoimmune cytopenias requiring treatment with medications

          -  At least one of the following: Autoimmune Neutropenia, Autoimmune Hemolytic Anemia,
             and/or Autoimmune Thrombocytopenia

          -  Must be proven autoimmune by either a documented autoantibody (positive direct anti
             globulin test, positive anti-neutrophil, and/or anti-platelet antibody) and/or a
             documented clinical response to immunosuppression

          -  Autoimmune Cytopenias can be idiopathic (Idiopathic Thrombocytopenic Purpura (ITP),
             Autoimmune Hemolytic Anemia (AIHA), Autoimmune Neutropenia (AIN), or Evans syndrome)
             or secondary to one of following conditions: Lupus, Rheumatoid Arthritis (RA), ALPS
             (Autoimmune Lymphoproliferative Syndrome), or Inflammatory bowel disease (IBD)

          -  Patients must have chronic disease diagnosed by either a documented cytopenia syndrome
             (Lupus, ALPS, RA, or IBD), or by having Evans syndrome defined as idiopathic
             destruction of multiple blood cell types, and/or by having disease &gt;6 months

          -  Patients must be refractory to or unable to tolerate standard front-line therapies for
             autoimmune cytopenias (corticosteroids and/or IVIG)

          -  Patients may be taking second-line agents for autoimmune cytopenias (mycophenolate
             mofetil, cyclosporine, tacrolimus, mercaptopurine, and/or methotrexate) at time of
             study entry; however, attempts should be made to wean these agents. Patients may not
             stay on a combination of sirolimus and a calcineurin inhibitor for greater than 4
             weeks

          -  Informed consent/assent must be obtained prior to initiating treatment

          -  Patient must be able to consume oral medication in the form of tablets or solution

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Uncontrolled infection

          -  Known allergy to Sirolimus or its components

          -  Patients with a documented malignancy on therapy or not in remission

          -  Patients who do not meet organ function requirements listed in protocol

          -  Patients with a documented history of severe combined immunodeficiency or human
             immunodeficiency virus infection (HIV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Teachey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Teachey DT, Obzut DA, Axsom K, Choi JK, Goldsmith KC, Hall J, Hulitt J, Manno CS, Maris JM, Rhodin N, Sullivan KE, Brown VI, Grupp SA. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS). Blood. 2006 Sep 15;108(6):1965-71. Epub 2006 Jun 6.</citation>
    <PMID>16757690</PMID>
  </reference>
  <reference>
    <citation>Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, McMann JM, Sullivan KE, Travis SF, Grupp SA. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005 Mar 15;105(6):2443-8. Epub 2004 Nov 12.</citation>
    <PMID>15542578</PMID>
  </reference>
  <results_reference>
    <citation>Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009 Apr;145(1):101-6. doi: 10.1111/j.1365-2141.2009.07595.x. Epub 2009 Feb 4.</citation>
    <PMID>19208097</PMID>
  </results_reference>
  <results_reference>
    <citation>Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. doi: 10.1182/blood-2015-07-657981. Epub 2015 Oct 26.</citation>
    <PMID>26504182</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <results_first_submitted>June 1, 2017</results_first_submitted>
  <results_first_submitted_qc>November 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2017</results_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALPS</keyword>
  <keyword>Autoimmune</keyword>
  <keyword>Cytopenias</keyword>
  <keyword>Treatment</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Rapamycin</keyword>
  <keyword>Lymph Nodes</keyword>
  <keyword>Spleen</keyword>
  <keyword>Hemolytic Anemia</keyword>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>ITP</keyword>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus Treatment</title>
          <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus Treatment</title>
          <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="1.8" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus</title>
        <description>Grade 3 toxicities are those that are considered severe or medically equivalent requiring hospitalization or prolonged hospitalization (according to CTCAE criteria 3.0).
Grade 4 toxicities are those that are life-threatening (urgent intervention indicated) (according to CTCAE criteria 3.0).</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Treatment</title>
            <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus</title>
          <description>Grade 3 toxicities are those that are considered severe or medically equivalent requiring hospitalization or prolonged hospitalization (according to CTCAE criteria 3.0).
Grade 4 toxicities are those that are life-threatening (urgent intervention indicated) (according to CTCAE criteria 3.0).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Autoimmune Disease Response to Oral Sirolimus</title>
        <description>Complete response (CR) is complete resolution in all autoimmune cytopenias (neutropenia, anemia thrombocytopenia) maintained for more than two months, combined with an ability to wean off corticosteroids and/or other immunosuppressive medication. Partial response (PR) is improvement in any cytopenias by at least one grade, lasting more than two months, without worsening any other cytopenias or stable disease with the ability to wean corticosteroids and/or immunosuppressive medications by at least 50%. No response (NR) is no change in cytopenias with treatment, and the inability to wean corticosteroids or other immunosuppressive medications. Progressive disease (PD) refers to obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug.</description>
        <time_frame>6 months</time_frame>
        <population>Number analyzed per row reflects number of participants with each condition</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Treatment</title>
            <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Autoimmune Disease Response to Oral Sirolimus</title>
          <description>Complete response (CR) is complete resolution in all autoimmune cytopenias (neutropenia, anemia thrombocytopenia) maintained for more than two months, combined with an ability to wean off corticosteroids and/or other immunosuppressive medication. Partial response (PR) is improvement in any cytopenias by at least one grade, lasting more than two months, without worsening any other cytopenias or stable disease with the ability to wean corticosteroids and/or immunosuppressive medications by at least 50%. No response (NR) is no change in cytopenias with treatment, and the inability to wean corticosteroids or other immunosuppressive medications. Progressive disease (PD) refers to obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug.</description>
          <population>Number analyzed per row reflects number of participants with each condition</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response in patients w/ ALPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response in patients w/ multilineage cytopenias</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resp pts w/ single-lineage autoimmune cytopenias</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels Produced by Administration of Oral Sirolimus</title>
        <description>Pharmacokinetic levels produced by administration of oral sirolimus</description>
        <time_frame>Within first 5 days of starting sirolimus</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Treatment</title>
            <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels Produced by Administration of Oral Sirolimus</title>
          <description>Pharmacokinetic levels produced by administration of oral sirolimus</description>
          <units>nanograms/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="2.9" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Sirolimus on Intracellular Targets</title>
        <description>Needs more specific information</description>
        <time_frame>6 months</time_frame>
        <population>This was an optional assessment- there was no enrollment. Data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Treatment</title>
            <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Sirolimus on Intracellular Targets</title>
          <description>Needs more specific information</description>
          <population>This was an optional assessment- there was no enrollment. Data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Lymphoproliferation Response to Oral Sirolimus</title>
        <description>Complete response (CR) is complete resolution of any lymphadenopathy and splenomegaly for at least two months. Partial response (PR) is a reduction in size of at least 50% of lymphadenopathy or splenomegaly for at least two months. No response (NR) is no change or &lt; 50% reduction in lymphadenopathy or splenomegaly. Progressive Disease (PD) is obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug. Not Applicable (N/A) is there is no evidence of disease (No pathologic lymphadenopathy or splenomegaly at time of enrollment).</description>
        <time_frame>6 months</time_frame>
        <population>Number analyzed per row reflects number of participants with each condition</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus Treatment</title>
            <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Lymphoproliferation Response to Oral Sirolimus</title>
          <description>Complete response (CR) is complete resolution of any lymphadenopathy and splenomegaly for at least two months. Partial response (PR) is a reduction in size of at least 50% of lymphadenopathy or splenomegaly for at least two months. No response (NR) is no change or &lt; 50% reduction in lymphadenopathy or splenomegaly. Progressive Disease (PD) is obtaining a CR or PR by the 3 month observation and relapsing or progressing by the 6 month observation, leading to cessation of study drug. Not Applicable (N/A) is there is no evidence of disease (No pathologic lymphadenopathy or splenomegaly at time of enrollment).</description>
          <population>Number analyzed per row reflects number of participants with each condition</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Response in patients w/ ALPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable (N/A)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Response in patients w/ multilineage cytopenias</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable (N/A)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>esp pts w/ single-lineage autoimmune cytopenias</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Complete Response (CR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response (PR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response (NR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive disease (PD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Applicable (N/A)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus Treatment</title>
          <description>Sirolimus treatment
sirolimus: Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <description>This adverse event was determined not to be related to study treatment.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated triglycerides and cholesterol</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastro-esophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sun sensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David T. Teachey, MD</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>267-426-5802</phone>
      <email>teacheyd@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

